Rare Daily Staff
Kaleido Biosciences said it closed a $101 million series C financing to expand its platform and advance its pipeline of experimental therapies targeting the microbiome including its lead candidate to treat urea cycle disorders.
Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority, Fidelity Management and Research Company, Invus, and Rock Springs Capital. These investors joined Kaleido’s founder, Flagship Pioneering, and a number of undisclosed investors.
To date, microbiome therapeutic strategies have focused primarily on adding or subtracting bacteria to influence the trillions of microbes that make up the gut microbiome. Kaleido is the first company to develop novel chemistries to systematically drive functions of the microbiome organ. Kaleido’s Microbiome Metabolic Therapies direct these functional outputs to treat disease and improve overall health. The company is advancing a pipeline of candidates in multiple therapeutic areas, including rare genetic disorders.
“We are pleased to have support from our new and existing investors who share Kaleido’s excitement in leveraging the therapeutic potential of the microbiome and the promise of accelerating the discovery and development of products for patients,” said Michael Bonney, CEO and chair of Kaleido.
June 27, 2018
Photo: Michael Bonney, CEO and chair of Kaleido